{"id":"https://openalex.org/W4400965307","doi":"https://doi.org/10.1136/bmjophth-2024-001702","title":"Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis","display_name":"Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis","publication_year":2024,"publication_date":"2024-07-01","ids":{"openalex":"https://openalex.org/W4400965307","doi":"https://doi.org/10.1136/bmjophth-2024-001702","pmid":"https://pubmed.ncbi.nlm.nih.gov/39043575","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11268043"},"language":"en","primary_location":{"id":"doi:10.1136/bmjophth-2024-001702","doi":"https://doi.org/10.1136/bmjophth-2024-001702","is_oa":true,"landing_page_url":"https://doi.org/10.1136/bmjophth-2024-001702","pdf_url":"https://bmjophth.bmj.com/content/bmjophth/9/1/e001702.full.pdf","source":{"id":"https://openalex.org/S4210181307","display_name":"BMJ Open Ophthalmology","issn_l":"2397-3269","issn":["2397-3269"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Ophthalmology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://bmjophth.bmj.com/content/bmjophth/9/1/e001702.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026464612","display_name":"Daniel Samac\u00e1-Samac\u00e1","orcid":"https://orcid.org/0000-0002-0782-4315","observed_orcids":["https://orcid.org/0000-0002-0782-4315"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Daniel Samac\u00e1-Samac\u00e1","raw_affiliation_strings":["Evidence Generation, Roche Colombia, Bogot\u00e1 D.C, Colombia"],"raw_orcid":"https://orcid.org/0000-0002-0782-4315","affiliations":[{"raw_affiliation_string":"Evidence Generation, Roche Colombia, Bogot\u00e1 D.C, Colombia","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5120851591","display_name":"Claudia Hern\u00e1ndez-Castillo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claudia Hern\u00e1ndez-Castillo","raw_affiliation_strings":["Real World Insights, IQVIA Solutions, Bogot\u00e1 D.C, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Real World Insights, IQVIA Solutions, Bogot\u00e1 D.C, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017430551","display_name":"Laura Prieto\u2010Pinto","orcid":"https://orcid.org/0000-0002-9489-2585","observed_orcids":["https://orcid.org/0000-0002-9489-2585"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Laura Prieto-Pinto","raw_affiliation_strings":["Evidence Generation, Roche Colombia, Bogot\u00e1 D.C, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidence Generation, Roche Colombia, Bogot\u00e1 D.C, Colombia","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Francisco Rodr\u00edguez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I90803817","display_name":"Universidad del Rosario","ror":"https://ror.org/0108mwc04","country_code":"CO","type":"education","lineage":["https://openalex.org/I90803817"]}],"countries":["CO"],"is_corresponding":false,"raw_author_name":"Francisco Rodr\u00edguez","raw_affiliation_strings":["Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogot\u00e1 D.C, Colombia","FUNDONAL, Bogota, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogot\u00e1 D.C, Colombia","institution_ids":["https://openalex.org/I90803817"]},{"raw_affiliation_string":"FUNDONAL, Bogota, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045508507","display_name":"Carolina Sardi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolina Sardi","raw_affiliation_strings":["Instituto Nacional de Investigaci\u00f3n en Oftalmolog\u00eda, Medell\u00edn, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Nacional de Investigaci\u00f3n en Oftalmolog\u00eda, Medell\u00edn, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007726948","display_name":"Hugo Hern\u00e1n Ocampo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hugo Ocampo","raw_affiliation_strings":["Cl\u00ednica de Oftalmolog\u00eda, Cali, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cl\u00ednica de Oftalmolog\u00eda, Cali, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001015080","display_name":"Joshua Kock","orcid":"https://orcid.org/0000-0002-5079-3585","observed_orcids":["https://orcid.org/0000-0002-5079-3585"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Joshua Kock","raw_affiliation_strings":["Evidence Generation, Roche Colombia, Bogot\u00e1 D.C, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidence Generation, Roche Colombia, Bogot\u00e1 D.C, Colombia","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":null,"display_name":"Fabi\u00e1n Hern\u00e1ndez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fabi\u00e1n Hern\u00e1ndez","raw_affiliation_strings":["Real World Insights, IQVIA Solutions, Bogot\u00e1 D.C, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Real World Insights, IQVIA Solutions, Bogot\u00e1 D.C, Colombia","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5026464612"],"corresponding_institution_ids":["https://openalex.org/I118019719"],"apc_list":{"value":1700,"currency":"GBP","value_usd":2085},"apc_paid":{"value":1700,"currency":"GBP","value_usd":2085},"fwci":1.254,"has_fulltext":true,"cited_by_count":17,"citation_normalized_percentile":{"value":0.76995708,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":98,"max":99},"biblio":{"volume":"9","issue":"1","first_page":"e001702","last_page":"e001702"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/faricimab","display_name":"faricimab","score":1.0},{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":1.0},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9850000143051147},{"id":"https://openalex.org/keywords/brolucizumab","display_name":"brolucizumab","score":0.8460000157356262},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.972000002861023},{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/visual-acuity","display_name":"visual acuity","score":0.8199999928474426},{"id":"https://openalex.org/keywords/retinal-thickness","display_name":"retinal thickness","score":0.9649999737739563},{"id":"https://openalex.org/keywords/retinal-fluid","display_name":"retinal fluid","score":0.6539999842643738},{"id":"https://openalex.org/keywords/treatment-frequency","display_name":"treatment frequency","score":0.6029999852180481},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.48100000619888306}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8793761730194092},{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.7477226257324219},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.7402237057685852},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7214184403419495},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.693321704864502},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.6433855295181274},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6293573379516602},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.624065101146698},{"id":"https://openalex.org/C2779829184","wikidata":"https://www.wikidata.org/wiki/Q631361","display_name":"Diabetic retinopathy","level":3,"score":0.58282870054245},{"id":"https://openalex.org/C2780699112","wikidata":"https://www.wikidata.org/wiki/Q7246796","display_name":"Pro re nata","level":5,"score":0.5679370760917664},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.5522949695587158},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.46183323860168457},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3607652187347412},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34955310821533203},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.15298527479171753},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.0},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014792","descriptor_name":"Visual Acuity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1136/bmjophth-2024-001702","doi":"https://doi.org/10.1136/bmjophth-2024-001702","is_oa":true,"landing_page_url":"https://doi.org/10.1136/bmjophth-2024-001702","pdf_url":"https://bmjophth.bmj.com/content/bmjophth/9/1/e001702.full.pdf","source":{"id":"https://openalex.org/S4210181307","display_name":"BMJ Open Ophthalmology","issn_l":"2397-3269","issn":["2397-3269"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Ophthalmology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11268043","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11268043","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11268043/pdf/bmjophth-9-1.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Ophthalmol","raw_type":"Text"},{"id":"pmid:39043575","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39043575","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ open ophthalmology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:af7e7198d46a47778a6e52ac92aa3b85","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/af7e7198d46a47778a6e52ac92aa3b85","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"BMJ Open Ophthalmology, Vol 9, Iss 1 (2024)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/bmjophth-2024-001702","doi":"https://doi.org/10.1136/bmjophth-2024-001702","is_oa":true,"landing_page_url":"https://doi.org/10.1136/bmjophth-2024-001702","pdf_url":"https://bmjophth.bmj.com/content/bmjophth/9/1/e001702.full.pdf","source":{"id":"https://openalex.org/S4210181307","display_name":"BMJ Open Ophthalmology","issn_l":"2397-3269","issn":["2397-3269"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Ophthalmology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307779","display_name":"Roche","ror":"https://ror.org/00by1q217"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4400965307.pdf","grobid_xml":"https://content.openalex.org/works/W4400965307.grobid-xml"},"referenced_works_count":74,"referenced_works":["https://openalex.org/W78778186","https://openalex.org/W1481978003","https://openalex.org/W1500728559","https://openalex.org/W1504183466","https://openalex.org/W1574902248","https://openalex.org/W1583073219","https://openalex.org/W1782061354","https://openalex.org/W1968189763","https://openalex.org/W1969775043","https://openalex.org/W1973149924","https://openalex.org/W1974777756","https://openalex.org/W1979356478","https://openalex.org/W1996171994","https://openalex.org/W1999485239","https://openalex.org/W2003043596","https://openalex.org/W2004117352","https://openalex.org/W2013705308","https://openalex.org/W2020732840","https://openalex.org/W2042649412","https://openalex.org/W2059547624","https://openalex.org/W2080886828","https://openalex.org/W2116794040","https://openalex.org/W2124415048","https://openalex.org/W2170468054","https://openalex.org/W2171962482","https://openalex.org/W2172453889","https://openalex.org/W2396116581","https://openalex.org/W2556922900","https://openalex.org/W2567362164","https://openalex.org/W2572724662","https://openalex.org/W2583173070","https://openalex.org/W2605943608","https://openalex.org/W2616502721","https://openalex.org/W2619267093","https://openalex.org/W2753708825","https://openalex.org/W2773727567","https://openalex.org/W2898576383","https://openalex.org/W2914285558","https://openalex.org/W2914616519","https://openalex.org/W2915852396","https://openalex.org/W2936430874","https://openalex.org/W2939023004","https://openalex.org/W2953647828","https://openalex.org/W2969630964","https://openalex.org/W2973401311","https://openalex.org/W2974747689","https://openalex.org/W2987790686","https://openalex.org/W2999057392","https://openalex.org/W3011743134","https://openalex.org/W3012000803","https://openalex.org/W3015163167","https://openalex.org/W3035836792","https://openalex.org/W3046457241","https://openalex.org/W3083332113","https://openalex.org/W3113586038","https://openalex.org/W3146812839","https://openalex.org/W3152706196","https://openalex.org/W3157651190","https://openalex.org/W3191480438","https://openalex.org/W3193329895","https://openalex.org/W4206959584","https://openalex.org/W4229336372","https://openalex.org/W4240484632","https://openalex.org/W4250031098","https://openalex.org/W4281618856","https://openalex.org/W4288080402","https://openalex.org/W4291017120","https://openalex.org/W4324316634","https://openalex.org/W4376276190","https://openalex.org/W4378233139","https://openalex.org/W4378515790","https://openalex.org/W4385879495","https://openalex.org/W4390935816","https://openalex.org/W4399437467"],"related_works":["https://openalex.org/W7223182815","https://openalex.org/W7119513336","https://openalex.org/W4410267511","https://openalex.org/W4391360858","https://openalex.org/W4389818728","https://openalex.org/W4413361503","https://openalex.org/W7152641944","https://openalex.org/W4399397943","https://openalex.org/W4414426137","https://openalex.org/W4383301634"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,79,88,91,113,120,128,201,217,231],"efficacy":[4,164,254],"and":[5,46,71,78,90,104,137,169,195,198,203,223,255,267],"safety":[6,214,256],"of":[7,60,69,93,130,219],"faricimab":[8,182,238],"compared":[9,133,189,264],"with":[10,116,134,181,190,233,258,265],"other":[11,166],"anti-vascular":[12],"endothelial":[13],"growth":[14],"factor":[15],"(anti-VEGF)":[16],"agents":[17],"in":[18,55,81,119,127,148,200,236,253,261],"treating":[19],"neovascular":[20],"age-related":[21],"macular":[22],"degeneration":[23],"(nAMD)":[24],"patients.":[25,279],"METHODS":[26],"AND":[27],"ANALYSIS:":[28],"A":[29],"systematic":[30],"review":[31],"(SR)":[32],"was":[33],"conducted":[34],"up":[35],"to":[36,165,172],"January":[37],"2023.":[38],"Network":[39,82],"meta-analyses":[40],"(NMA)":[41],"were":[42,85,183],"performed,":[43],"including":[44],"sensitivity":[45],"subgroup":[47],"analyses":[48],"for":[49,87,230,243,277],"na\u00efve":[50],"population.":[51],"Outcomes":[52],"included":[53,118],"changes":[54],"visual":[56,149],"acuity":[57,150],"(Early":[58],"Treatment":[59],"Diabetic":[61],"Retinopathy":[62],"Study":[63],"[ETDRS]":[64],"letters),":[65],"anatomical":[66],"changes,":[67],"frequency":[68],"injections":[70,132,263],"adverse":[72,221,226],"events.":[73],"The":[74],"Cochrane":[75],"Collaboration":[76],"guidelines":[77],"Confidence":[80],"Meta-Analysis":[83],"framework":[84],"used":[86],"SR":[89],"certainty":[92],"evidence,":[94],"respectively.":[95],"RESULTS:":[96],"From":[97],"4128":[98],"identified":[99],"records":[100],"through":[101,151],"electronic":[102],"databases":[103],"complementary":[105],"searches,":[106],"63":[107],"randomised":[108],"controlled":[109],"trials":[110],"(RCTs)":[111],"met":[112],"eligibility":[114],"criteria,":[115],"42":[117],"NMA.":[121],"Faricimab":[122,210,247],"showed":[123,162,176,211,239,248],"a":[124,156,212,240,249,259,273],"significant":[125,146,241],"reduction":[126,242,260],"number":[129],"annual":[131,262],"most":[135],"fixed":[136,202,266],"flexible":[138,268],"anti-VEGF":[139,167,269],"treatment":[140,275],"regimens,":[141,271],"while":[142],"showing":[143],"no":[144],"statistically":[145],"differences":[147],"ETDRS":[152],"letter":[153],"gain,":[154],"demonstrating":[155],"comparable":[157,163,213,250],"efficacy.":[158],"Retinal":[159],"thickness":[160],"results":[161],"agents,":[168],"inferior":[170],"only":[171],"brolucizumab.":[173],"Results":[174],"also":[175],"that":[177],"more":[178],"patients":[179],"treated":[180],"free":[184],"from":[185],"post-treatment":[186],"retinal":[187],"fluid":[188],"aflibercept":[191],"every":[192],"8":[193],"weeks,":[194],"both":[196],"ranibizumab":[197],"bevacizumab,":[199],"pro":[204],"re":[205],"nata":[206],"(PRN)":[207],"assessed":[208],"schedules.":[209],"profile":[215],"regarding":[216],"risk":[218],"ocular":[220,225],"events":[222,227],"serious":[224],"(SOAE),":[228],"except":[229],"comparison":[232],"brolucizumab":[234],"quarterly,":[235],"which":[237],"SOAE":[244],"risk.":[245],"CONCLUSION:":[246],"clinical":[251],"benefit":[252],"outcomes,":[257],"drug":[270],"representing":[272],"valuable":[274],"option":[276],"nAMD":[278],"PROSPERO":[280],"REGISTRATION":[281],"NUMBER:":[282],"CRD42023394226.":[283]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":11}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2024-07-25T00:00:00"}